Literature DB >> 31201638

Xenobiotic Response Elements (XREs) from Human CYP1A1 Gene Enhance the hTERT Promoter Activity.

M V Shepelev1, S V Kalinichenko2, E K Saakian2, I V Korobko2.   

Abstract

A hybrid 6XRE-hTERT promoter consisting of the hTERT tumor-specific promoter and six copies of the XRE element from the CYP1A1 human gene promoter was created. Using a human lung cancer cells as a model, we showed that XRE elements in the hybrid promoter greatly increase the activity of the hTERT promoter and ensure the reporter gene transcriptional activation in response to the treatment of the cells with the AhR ligand benzo(a)pyrene. However, similar effects were also observed in normal human bronchial epithelial cells HBEpC, which indicates the loss of the tumor-specific activity by the 6XRE-hTERT hybrid promoter. XRE elements can be used for nonspecific transcription enhancement but are unsuitable for the creation of tumor-specific promoters with enhanced activity.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31201638     DOI: 10.1134/S1607672919020200

Source DB:  PubMed          Journal:  Dokl Biochem Biophys        ISSN: 1607-6729            Impact factor:   0.788


  9 in total

1.  Activation of telomerase in BeWo cells by estrogen and 2,3,7,8-tetrachlorodibenzo-p-dioxin in co-operation with c-Myc.

Authors:  Poonam Sarkar; Kazuhiro Shiizaki; Junzo Yonemoto; Hideko Sone
Journal:  Int J Oncol       Date:  2006-01       Impact factor: 5.650

Review 2.  Aryl hydrocarbon receptor ligands in cancer: friend and foe.

Authors:  Iain A Murray; Andrew D Patterson; Gary H Perdew
Journal:  Nat Rev Cancer       Date:  2014-12       Impact factor: 60.716

3.  hTERT and BIRC5 gene promoters for cancer gene therapy: A comparative study.

Authors:  Mikhail V Shepelev; Eugene P Kopantzev; Tatiana V Vinogradova; Eugene D Sverdlov; Igor V Korobko
Journal:  Oncol Lett       Date:  2016-06-15       Impact factor: 2.967

4.  Oncolysis and suppression of tumor growth by a GFP-expressing oncolytic adenovirus controlled by an hTERT and CMV hybrid promoter.

Authors:  J J Davis; L Wang; F Dong; L Zhang; W Guo; F Teraishi; K Xu; L Ji; B Fang
Journal:  Cancer Gene Ther       Date:  2006-02-17       Impact factor: 5.987

5.  A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer.

Authors:  Thomas Wirth; Lars Zender; Bernd Schulte; Bettina Mundt; Ruben Plentz; Karl Lenhard Rudolph; Michael Manns; Stefan Kubicka; Florian Kühnel
Journal:  Cancer Res       Date:  2003-06-15       Impact factor: 12.701

Review 6.  Telomerase-specific oncolytic virotherapy for human cancer with the hTERT promoter.

Authors:  Toshiyoshi Fujiwara; Yasuo Urata; Noriaki Tanaka
Journal:  Curr Cancer Drug Targets       Date:  2007-03       Impact factor: 3.428

7.  Functional analysis of the dioxin response elements (DREs) of the murine CYP1A1 gene promoter: beyond the core DRE sequence.

Authors:  Shuaizhang Li; Xinhui Pei; Wen Zhang; Heidi Qunhui Xie; Bin Zhao
Journal:  Int J Mol Sci       Date:  2014-04-16       Impact factor: 5.923

8.  A Novel Hybrid Promoter ARE-hTERT for Cancer Gene Therapy.

Authors:  S V Kalinichenko; M V Shepelev; P N Vikhreva; I V Korobko
Journal:  Acta Naturae       Date:  2017 Oct-Dec       Impact factor: 1.845

Review 9.  Gene Therapies for Cancer: Strategies, Challenges and Successes.

Authors:  Swadesh K Das; Mitchell E Menezes; Shilpa Bhatia; Xiang-Yang Wang; Luni Emdad; Devanand Sarkar; Paul B Fisher
Journal:  J Cell Physiol       Date:  2015-02       Impact factor: 6.384

  9 in total
  2 in total

1.  Downregulation of hTERT contributes to ovarian cancer apoptosis and inhibits proliferation of ovarian cancer cells.

Authors:  Qing-An-Zi Wang; Xiaolei Liang; Yongxiu Yang
Journal:  Transl Cancer Res       Date:  2020-03       Impact factor: 1.241

2.  Enhancement of nanoparticle-mediated double suicide gene expression driven by 'E9-hTERT promoter' switch in dedifferentiated thyroid cancer cells.

Authors:  Aoshuang Chang; Junjun Ling; Huiping Ye; Houyu Zhao; Xianlu Zhuo
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.